# Botulinum Toxin Injections for Drooling Improve Dysphagia in Patients with Parkinson’s Disease

**Authors:** Domenico Antonio Restivo, Mario Stampanoni Bassi, Angelo Alito, Simona Portaro, Adriana Tisano, Salvatore Greco, Rosario Marchese-Ragona, Angelo Quartarone

PMC · DOI: 10.3390/toxins18020073 · Toxins · 2026-02-02

## TL;DR

Injecting botulinum toxin into salivary glands reduces drooling and improves swallowing in Parkinson's disease patients.

## Contribution

This study shows that botulinum toxin injections can improve both drooling and dysphagia in Parkinson’s disease.

## Key findings

- Botulinum toxin injections reduced drooling in Parkinson’s disease patients.
- Clinical and neurophysiological measures of dysphagia improved after treatment.
- Swallowing function improvements may result from better saliva management.

## Abstract

Drooling and dysphagia are frequent and disabling complications in Parkinson’s disease (PD) and often coexist, with drooling mainly resulting from impaired saliva clearance due to reduced oral motor control and potentially worsening swallowing function. This study aimed to evaluate whether botulinum toxin type A (BoNT/A) injections into the major salivary glands, beyond controlling drooling, could also improve swallowing performance using clinical and neurophysiological measures. Twenty PD patients with severe drooling and dysphagia underwent bilateral ultrasound-guided BoNT/A injections into the parotid and submandibular glands. Assessments were performed at baseline and at 1, 8, and 12 weeks post-injection. Dysphagia severity was evaluated using the Penetration–Aspiration Scale and the Dysphagia Severity Rating Scale. Neurophysiological assessment included electromyographic recordings from suprahyoid/submental and cricopharyngeal muscles, together with mechanomyography analysis of laryngeal movement during swallowing. Following BoNT/A treatment, a consistent reduction in drooling was observed, accompanied by significant improvements in clinical dysphagia scores and neurophysiological swallowing parameters across all follow-up time points. These findings suggest that incobotulinumtoxinA injections into salivary glands not only reduce drooling but also enhance swallowing function in PD patients, possibly by facilitating oral floor and oropharyngeal motor coordination secondary to improved saliva management.

## Linked entities

- **Diseases:** Parkinson’s disease (MONDO:0005180)

## Full-text entities

- **Diseases:** muscle hyperactivity (MESH:D009135), dysfunction (MESH:D006331), impairment of oral intake (MESH:D000080146), aspiration (MESH:D011015), cognitive impairment (MESH:D003072), Movement Disorder (MESH:D009069), rigidity (MESH:D009127), esophagus (MESH:D004938), death (MESH:D003643), malnutrition (MESH:D044342), bradykinesia (MESH:D018476), Dysphagia (MESH:D003680), dehydration (MESH:D003681), weight loss (MESH:D015431), Drooling (MESH:D012798), UES hyperactivity (MESH:D004941), neurological disorders (MESH:D009461), PD (MESH:D010300), neurological conditions (MESH:D019636), injury to (MESH:D014947), structural abnormalities of the oropharynx (MESH:D009959), impaired saliva clearance (MESH:D060825)
- **Chemicals:** barium (MESH:D001464), dopamine (MESH:D004298), levodopa (MESH:D007980), acetylcholine (MESH:D000109), water (MESH:D014867)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12945032/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC12945032/full.md

---
Source: https://tomesphere.com/paper/PMC12945032